MedDataX Logo

The Prediction of Preeclampsia/Toxemia in Twin Pregnancy

NCT ID: NCT01255202

Last Updated: 2010-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-09-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to finout whetere uterinae artery flow , PP13 and endogolin levels in the serum and kongo red in the urine can predict preeclamsia toxemia in twin pregnancies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia/Toxemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

preeclampsia toxemia twin pregnancy pp13 prediction kongo red

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

twin preganacies

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a women with a vaiable twin pregnany

Exclusion Criteria

* women with thrombophilya
* women terated with anticoagolant
* women with vascular disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Assaf-Harofeh Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assaf Harofe Medical Center

Zrifin, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ran Svirsky, MD

Role: CONTACT

Phone: 972-8-9779000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ran Svirsky, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

189/09

Identifier Type: -

Identifier Source: org_study_id